Chemed Corporation (CHE) - Stock Analysis

Last updated: Apr 25, 2026

HealthcareActive

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Healthcare services beat-and-raise candidate: Q1 2026 revenue and adjusted EPS beat estimates, full-year guidance was raised, VITAS growth remained strong with admissions up 6.9%, and the company added a new $300M buyback authorization.

Loading chart data...

Idea window: 4/28/2026 – 5/5/2026Sector: Healthcare

AI Analyst Overview

Last Price
$421.10
Market Cap
$5.65B
1D Return
-0.38%
YTD Return
-1.46%

Loading chart data...

Valuation Metrics

P/E
22.2
P/B
6.8
P/S
2.2
EV/EBITDA
14.0
Div Yield
0.55%

Fundamental Analysis

8.0

Key Financial Insights: • Strong margins • Healthy cash flow • Low leverage CHE combines strong profitability, solid cash generation, and low leverage, but its moderate liquidity and full valuation temper the investment case.

profitability
valuation

Price Behavior

7.0

Key Price Behavior Insights: • Breakout confirmation • Key support hold • Short-term overextension Support Level: $373–$377 Resistance Level: $390–$395 CHE is constructive over the last month after breaking above the $390–$395 resistance zone, but it may be short-term overextended and needs to hold above the $373–$377 support area to confirm the breakout.

bullish
breakout

Sentiment & News

6.0

Key News Insights: • Earnings beat • VITAS strength • Roto weakness Chemed's shares were pressured ahead of earnings, but Q1 2026 results beat estimates, VITAS strength drove a guidance raise, and capital actions plus acquisitions support the long-term outlook.

EarningsBeat
GuidanceRaise
AI

AI Summary

7.0
Positive

CHE should now be viewed less as a cap-risk turnaround and more as a VITAS-led quality compounder, with the key question being whether hospice growth and cash generation can outpace Roto-Rooter's margin drag and support a still-premium valuation; the upside is intact, but execution at VITAS and stabilization in Roto-Rooter are now the decisive catalysts.

GrowthOpportunity
ExecutionRisk
Valuation
AI summary updated 3 days ago

Description

Chemed Corporation delivers hospice and palliative care through a multidisciplinary network of clinicians, aides, social workers, clergy and volunteers across the United States under its VITAS segment, and provides plumbing, drain, excavation and water-restoration services to residential and commercial customers via company branches, independent contractors and franchisees under its Roto-Rooter segment. The company operates these two distinct businesses from its headquarters in Cincinnati and has been incorporated since 1970.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Apr 28May 5CHEChemed Corporation
Healthcare services beat-and-raise candidate: Q1 2026 revenue and adjusted EPS beat estimates, full-year guidance was raised, VITAS growth remained strong with admissions up 6.9%, and the company added a new $300M buyback authorization.
Active+0.0%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.